Authorized purpose: Automatically label, visualize, and quantify segmentable brain structures on single-time-point non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; output must be reviewed with the original images by a physician.
Clinical role
Post-acquisition automatic labeling, segmentation, visualization, and quantification with cloud processing and return of reviewable results to PACS.
Images and patients
CT/CTA · Brain (intracranial hyperdensities, lateral ventricles, and midline shift)
Key limitation
Keep in mind: Single-time-point NCCT only and limited to the stated intracranial hyperdensity, lateral-ventricle, and midline-shift structures. The output should be reviewed with the original images by a physician; overlay colors are visual differentiators only and have no independent meaning. The reviewed FDA text does not state a sample size or establish diagnostic sensitivity, specificity, or a clinical outcome claim.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatically label, visualize, and quantify segmentable brain structures on single-time-point non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; output must be reviewed with the original images by a physician.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain (intracranial hyperdensities, lateral ventricles, and midline shift) Input: DICOM non-contrast head CT series acquired at a single time point from a compliant imaging device or modality.
Who uses it?Intended users: Physicians.
What does the software produce?Output: DICOM summary and segmentation series: a summary slice with overlays and measurements, plus RGB segmentation overlays on the input series for intracranial hyperdensities and lateral ventricles with midline-shift information and volume measurements, returned with the original NCCT series to a preconfigured PACS.
What is its most important limitation?Key limitation: Single-time-point NCCT only and limited to the stated intracranial hyperdensity, lateral-ventricle, and midline-shift structures. The output should be reviewed with the original images by a physician; overlay colors are visual differentiators only and have no independent meaning. The reviewed FDA text does not state a sample size or establish diagnostic sensitivity, specificity, or a clinical outcome claim.
Clinical takeaway. Clinical role: Automatically label, visualize, and quantify segmentable brain structures on single-time-point non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; output must be reviewed with the original images by a physician.
Evidence takeaway. Evidence from the reviewed source record: FDA K232363 reports clinical testing against ground truth established by trained radiologists. Upper 95% CI bounds for mean absolute error were below 7.5 mL for total intracranial hyperdensity volume, 3 mL for each lateral-ventricle volume, and 2 mm for midline-shift distance. Dice lower confidence bounds exceeded 70% for hyperdensities and both lateral ventricles, with stratification by site, demographics, slice thickness, scanner, protocol, and estimated quantity; the reviewed FDA text does not state the study sample size.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatically label, visualize, and quantify segmentable brain structures on single-time-point non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; output must be reviewed with the original images by a physician.
DICOM summary and segmentation series: a summary slice with overlays and measurements, plus RGB segmentation overlays on the input series for intracranial hyperdensities and lateral ventricles with midline-shift information and volume measurements, returned with the original NCCT series to a preconfigured PACS.
Hospital radiology and PACS workflow; the FDA summary describes return to a hospital server or customer DICOM node but the indication does not restrict facility type.
Single-time-point NCCT only and limited to the stated intracranial hyperdensity, lateral-ventricle, and midline-shift structures. The output should be reviewed with the original images by a physician; overlay colors are visual differentiators only and have no independent meaning. The reviewed FDA text does not state a sample size or establish diagnostic sensitivity, specificity, or a clinical outcome claim.
FDA K232363 reports clinical testing against ground truth established by trained radiologists. Upper 95% CI bounds for mean absolute error were below 7.5 mL for total intracranial hyperdensity volume, 3 mL for each lateral-ventricle volume, and 2 mm for midline-shift distance. Dice lower confidence bounds exceeded 70% for hyperdensities and both lateral ventricles, with stratification by site, demographics, slice thickness, scanner, protocol, and estimated quantity; the reviewed FDA text does not state the study sample size.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K232363 reports clinical testing against ground truth established by trained radiologists. Upper 95% CI bounds for mean absolute error were below 7.5 mL for total intracranial hyperdensity volume, 3 mL for each lateral-ventricle volume, and 2 mm for midline-shift distance. Dice lower confidence bounds exceeded 70% for hyperdensities and both lateral ventricles, with stratification by site, demographics, slice thickness, scanner, protocol, and estimated quantity; the reviewed FDA text does not state the study sample size.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Viz HDS, Viz Volume Plus, Viz ICH+ regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232363
IndependenceIndependence not established
K232363
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232363. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM non-contrast head CT series acquired at a single time point from a compliant imaging device or modality.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Viz HDS is hosted on Viz.ai's cloud server, receives NCCT head scans, and returns DICOM summary and segmentation series to a customer-configured DICOM node such as PACS. Exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Viz HDS as hosted in Viz.ai's cloud server, where customers send NCCT head scans for processing and results are sent back to a DICOM node (e.g. PACS) at the customer's site. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Viz HDS is hosted in Viz.ai’s cloud server. For customers that have Viz HDS enabled, when they send NCCT head scans to the server, the scans are directed to the HDS processor for analysis." … "At the end of the processing the results series are created and sent back to the customer’s site to a DICOM node (e.g. PACS) defined for that customer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM summary and segmentation series: a summary slice with overlays and measurements, plus RGB segmentation overlays on the input series for intracranial hyperdensities and lateral ventricles with midline-shift information and volume measurements, returned with the original NCCT series to a preconfigured PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM summary and segmentation series: a summary slice with overlays and measurements, plus RGB segmentation overlays on the input series for intracranial hyperdensities and lateral ventricles with midline-shift information and volume measurements, returned with the original NCCT series to a preconfigured PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Viz HDS as hosted in Viz.ai's cloud server, where customers send NCCT head scans for processing and results are sent back to a DICOM node (e.g. PACS) at the customer's site. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Viz HDS is hosted in Viz.ai’s cloud server. For customers that have Viz HDS enabled, when they send NCCT head scans to the server, the scans are directed to the HDS processor for analysis." … "At the end of the processing the results series are created and sent back to the customer’s site to a DICOM node (e.g. PACS) defined for that customer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Viz HDS is hosted on Viz.ai's cloud server, receives NCCT head scans, and returns DICOM summary and segmentation series to a customer-configured DICOM node such as PACS. Exact interfaces, versions, and local compatibility require confirmation.
Viz.ai's own news releases say the Viz.ai One platform completed a SOC 2 Type II + HIPAA audit (announced 2024-02-26) and received ISO 27001:2022 plus six other ISO certificates (announced 2024-07-10). These are vendor announcements; the report and certificates were not read, and certificate dates may have lapsed or renewed since.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Viz.ai's trust center states that its assurance program includes continuously monitored controls, SOC 2 Type II coverage that includes the availability criterion for Viz.ai production systems and supporting infrastructure, ISO 22301 business continuity certification to ensure uninterrupted clinical workflows, and ISO 27035 incident management certification.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. Certificates and audit reports were not read; the trust center names Viz.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Viz HDS, Viz Volume Plus, Viz ICH+; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232363 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Automatic labeling, visualization, and quantification of segmentable brain structures from non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; single-timepoint volumes and longitudinal comparisons are provided when scans use the same scanner and protocol for the same person.
Modality
CT/CTA
Anatomy
Brain; intracranial hyperdensities, lateral ventricles, and midline shift
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.
Authorized purpose: Provide quantitative perfusion information in brain tissue for suspected ischemic stroke patients using dynamic brain CT perfusion studies; medical imaging professionals use the information as additional data in the standard-of-care assessment, not as a standalone diagnostic tool.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.